Reducing administration of CHOP chemotherapy by two cycles appeared as effective as the standard six cycles for younger patients with…
News and Events
Andrew Pecora, M.D., shares his thoughts on the necessity of allogeneic transplants to MML patients
Dr. Pecora, chief innovation officer, professor and vice president of Cancer Services John Theurer Cancer Center, shares his thoughts on…
Hackensack Meridian Health Announces New Community Smoking Cessation Treatment Center (CSCTC) Initiative
Hackensack University Medical Center recently hosted the fourth Community Outreach and Engagement initiative to reduce cancer disparities. This event, which…
David Siegel, M.D., talks about the TOURMALINE-MM3 study and the treatment of multiple myeloma
David Siegel, M.D., hematologist/oncologist, Hackensack University Medical Center, John Theurer Cancer Center, talks about how the outcomes of the TOURMALINE-MM3…
Tatyana Feldman, M.D., regarding improvements in the treatment of CTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses improvements in the treatment of cutaneous…
Andre Goy, M.D., comments on the long-term outcome of acalabrutinib in MCL
Dr. Goy, chair and director of John Theurer Cancer Center, chief of the Division of Lymphoma, Hackensack University Medical Center,…
Photos: December’s Roundup of Charitable Giving in NJ
The Cannata Report’s 33rd Annual Awards & Charities Dinner raised $180,000 for Tackle Kids Cancer, a philanthropic program benefitting the…
OncLive® to Present State of the Science Summit™ on Immunotherapy, Precision Medicine & Neuroscience in Oncology
OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need…
A Mission to Tackle Kids Cancer
WNBC Anchor Bruce Beck speaks with the family of 2-year-old Addison, one of the inspirational children he met last year…
More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial
A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51…